Although you can enjoy much of this website without javascript, we highly recommend that you enable it
in order to experience all available features.

Cookies on What Doctors Don't Tell You

We set cookies so you can manage your account and navigate the site, and to remember your cookie preferences so that you don't keep getting this message. To accept cookies, just keep browsing,
otherwise use the links on the right to adjust your cookie settings or find out more.

New guidelines now define half of all adults as having dangerously high blood pressure, requiring drugs for the rest of their lives. Lynne McTaggart and Bryan Hubbard offer alternatives to your doctor's prescription

Don't let facts spoil the results

About the author:&nbsp

An investigation into drug-company influence on research studies they've funded revealed that the researchers were often encouraged to arrive at a 'favourable conclusion' even when the results and small print didn't warrant one

An investigation into drug-company influence on research studies they've funded revealed that the researchers were often encouraged to arrive at a 'favourable conclusion' even when the results and small print didn't warrant one. Interestingly, the drug company rarely asked for the study itself to be changed, which might puzzle the more observant reader.

Another common problem is 'ghosting', where an eminent professor agrees to put his name to the work of some unknown researcher. This adds credibility to the findings (especially if, as expected, they're favourable). It's unusual for the professor to ever have read the study.

Finally, as we've seen before on these pages, the suppression of papers is not uncommon if the findings are so unfavourable that even the gloss of a 'doctored' (no pun intended) conclusion cannot salvage it. Studies that discover that a drug is actually killing patients tend never to see the light of day.

These practices have become so rife that 470 editors and publishers of scientific and medical journals have formed a group dedicated to improving the scientific validity of submitted papers.

However, then there's the tricky issue of the millions of dollars of drug-company advertising in their magazines to consider, of course . . . (J Am Med Assoc, 2005; 294: 2287-8).